Palmitoylethanolamide Promotes White-to-Beige Conversion and Metabolic Reprogramming of Adipocytes: Contribution of PPAR-α.
adipocyte remodeling
beige adipocytes
brown and white adipose tissue
human adipose stromal cells
leptin signaling
peroxisome proliferator-activated receptor-a
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
31 Jan 2022
31 Jan 2022
Historique:
received:
21
12
2021
revised:
21
01
2022
accepted:
25
01
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
27
2
2022
Statut:
epublish
Résumé
The potential role of brown and beige adipose tissue against obesity has been recognized. Browning, or beiging of white adipose tissue (WAT) is associated with the remodeling of adipocytes and the improvement of their metabolic and secretory functions. Here, palmitoylethanolamide (PEA) restore the plasticity of brown and white adipocytes impaired in mice on a high-fat diet (HFD). Young male C57Bl/6J mice were fed with control (STD) diet or HFD for 12 weeks. Ultramicronized PEA (30 mg/kg/die p.o.) was administered for an additional 7 weeks, together with HFD. PEA recovered interscapular brown fat morphology and function, increasing UCP1 positivity, noradrenergic innervation, and inducing the mRNA transcription of several specialized thermogenic genes. PEA promotes the beige-conversion of the subcutaneous WAT, increasing thermogenic markers and restoring leptin signaling and tissue hormone sensitivity. The pivotal role of lipid-sensing peroxisome proliferator-activated receptor (PPAR)-α in PEA effects was determined in mature 3T3-L1. Moreover, PEA improved mitochondrial bioenergetics in mature adipocytes measured by a Seahorse analyzer and induced metabolic machinery via AMPK phosphorylation. All these outcomes were dampened by the receptor antagonist GW6471. Finally, PEA induced adipogenic differentiation and increased AMPK phosphorylation in human adipose-derived stromal cells (ASCs) obtained from subcutaneous WAT of normal-weight patients and patients with obesity. We identify PEA and PPAR-α activation as the main mechanism by which PEA can rewire energy-storing white into energy-consuming brown-like adipocytes via multiple and converging effects that restore WAT homeostasis and metabolic flexibility.
Identifiants
pubmed: 35214069
pii: pharmaceutics14020338
doi: 10.3390/pharmaceutics14020338
pmc: PMC8880285
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Physiol Rev. 2018 Oct 1;98(4):1911-1941
pubmed: 30067159
Nat Rev Mol Cell Biol. 2021 Jun;22(6):393-409
pubmed: 33758402
Endocrinology. 2014 Apr;155(4):1291-301
pubmed: 24428531
Front Endocrinol (Lausanne). 2021 May 18;12:585887
pubmed: 34084149
Cell Metab. 2016 Jul 12;24(1):118-29
pubmed: 27411013
Mol Metab. 2018 Aug;14:82-94
pubmed: 29935920
Nat Metab. 2019 Feb;1(2):189-200
pubmed: 31903450
Life Sci. 2015 Nov 1;140:64-74
pubmed: 26071010
Toxicol Appl Pharmacol. 2014 Sep 15;279(3):401-408
pubmed: 24978599
Cell. 2014 Jan 16;156(1-2):304-16
pubmed: 24439384
Sci Rep. 2017 Jul 26;7(1):6619
pubmed: 28747790
J Anat. 2009 Jan;214(1):171-8
pubmed: 19018882
Obesity (Silver Spring). 2010 Jan;18(1):55-62
pubmed: 19521349
Endocrinology. 2001 Oct;142(10):4195-202
pubmed: 11564675
Hormones (Athens). 2019 Jun;18(2):127-136
pubmed: 30414080
Cell Biochem Funct. 2015 Jun;33(4):249-56
pubmed: 25959716
Nat Rev Endocrinol. 2020 Jan;16(1):30-43
pubmed: 31776456
J Biol Chem. 2001 Jan 12;276(2):1486-93
pubmed: 11050084
Obes Rev. 2019 Feb;20(2):241-251
pubmed: 30450758
Annu Rev Immunol. 2011;29:415-45
pubmed: 21219177
Int J Mol Sci. 2018 Jul 21;19(7):
pubmed: 30037087
Nat Rev Drug Discov. 2016 Jun;15(6):405-24
pubmed: 26965204
J Biol Chem. 2011 Dec 16;286(50):43112-22
pubmed: 22033933
J Physiol. 1984 Oct;355:457-63
pubmed: 6491999
Nat Rev Mol Cell Biol. 2019 Apr;20(4):242-258
pubmed: 30610207
Am J Physiol Endocrinol Metab. 2017 Nov 1;313(5):E515-E527
pubmed: 28679625
FASEB J. 2020 Jan;34(1):350-364
pubmed: 31914699
FASEB J. 2020 Jan;34(1):676-690
pubmed: 31914696
Sci Rep. 2018 Sep 25;8(1):14365
pubmed: 30254326
J Obes. 2013;2013:409679
pubmed: 23533722
Nutr Metab (Lond). 2021 Apr 13;18(1):39
pubmed: 33849593
Curr Diab Rep. 2018 Aug 17;18(10):80
pubmed: 30120579
Nat Rev Endocrinol. 2019 Sep;15(9):507-524
pubmed: 31296970
Diabetes. 2010 Jan;59(1):105-9
pubmed: 19846802
Cell Transplant. 2015;24(11):2307-22
pubmed: 26531290
Diabetes. 2015 Jul;64(7):2369-75
pubmed: 26050669
Sci Rep. 2019 Mar 18;9(1):4832
pubmed: 30886232
JAKSTAT. 2013 Apr 1;2(2):e23878
pubmed: 24058813
Theranostics. 2020 Sep 14;10(24):11302-11323
pubmed: 33042284
Am J Physiol Endocrinol Metab. 2019 Mar 1;316(3):E487-E503
pubmed: 30576247
Trends Neurosci. 2021 Mar;44(3):189-202
pubmed: 33229051
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18011-6
pubmed: 16326804
Cell Metab. 2018 Jan 9;27(1):68-83
pubmed: 29320711
J Clin Endocrinol Metab. 2011 Mar;96(3):775-81
pubmed: 21190973
Stem Cell Res. 2016 Sep;17(2):342-351
pubmed: 27614132
Eur J Endocrinol. 2014 Apr 10;170(5):R159-71
pubmed: 24468979
Pharmacol Res. 2014 Aug;86:32-41
pubmed: 24844438
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12017-22
pubmed: 17609368
Br J Pharmacol. 2021 Feb;178(4):845-859
pubmed: 32346865
Genes Dev. 2012 Feb 1;26(3):271-81
pubmed: 22302939